Karyopharm Therapeutics Inc.
Company Stats
- Market Cap
- $27.7M
- as of Sep 30, 2026
- Shares Outstanding
- 22.7M
- Free Float
- 65.7%
Income Statement
- Revenue
- $146.1M
- Operating Income
- -$90.7M
- Net Income
- -$196.0M
- EBITDA
- -$90.4M
- Revenue Growth, 3Y
- -2.4%
- FCF Margin, 3Y Avg
- -67.7%
- FCF Margin, Worst Year
- -87.9%
Cash Flow
- Free Cash Flow
- -$75.4M
- FCF Yield
- -272.4%
- Owner FCF Yield
- -323.1%
Balance Sheet
- Cash & Equivalents
- $60.5M
Returns & Capital
- SBC, 3Y Avg
- $18.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $146.1M | -$75.4M | -51.6% |
| FY2024 | $145.2M | -$127.6M | -87.9% |
| FY2023 | $146.0M | -$92.7M | -63.5% |
| FY2022 | $157.1M | -$149.7M | -95.3% |
| FY2021 | $209.8M | -$107.3M | -51.2% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 30, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges